|
Mechanism5-HT receptor modulators [+2] |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Randomized, Double-Blind, Placebo-Controlled Study of Rezular (Arverapamil) in the Treatment of Irritable Bowel Syndrome With Diarrhea (IBS-D)
The purpose of the study is to determine the efficacy and safety of Rezular (arverapamil) in the treatment of IBS-D.
100 Clinical Results associated with AGI Therapeutics, Inc.
0 Patents (Medical) associated with AGI Therapeutics, Inc.
100 Deals associated with AGI Therapeutics, Inc.
100 Translational Medicine associated with AGI Therapeutics, Inc.